Novartis prepares for FDA submission for its chronic hives treatment
Following the Phase III trials for remibrutinib meeting their primary endpoints, Novartis plans for regulatory submissions in 2024.
10 August 2023
10 August 2023
Following the Phase III trials for remibrutinib meeting their primary endpoints, Novartis plans for regulatory submissions in 2024.
The transaction is anticipated to close in the third quarter of this year.
The agreement to sell Scilex Holding Company stocks would raise funds to pay off Sorrento’s debts.
The company has a pipeline of RNA therapeutics to treat diseases across a range of areas.
Celmatix and Aché Laboratórios have teamed up to develop melatonin receptor agonists for polycystic ovary syndrome (PCOS).
The proteins, which mimic those found in mother’s milk, target toxins released by harmful pathogens in the gut.
AGC has extended its Milan manufacturing facility to address the growing clinical trial and commercial demands.
We will be launching our new event Clinical Trials In Rare Diseases Conference 2023 at Princeton Marriott at Forrestal, New Jersey, USA on 13th-14th September! Bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions and much more. With over 40 solution providers this will be a perfect platform to reconnect with current business partners, meet new vendors and discover which new technologies are being employed to improve your Rare Disease clinical trials.
The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Give your business an edge with our leading industry insights.